Effects of renin-angiotensin system inhibitor type and dosage on survival after transcatheter aortic valve implantation.
Ulrich Fischer-RasokatCeline BänschMatthias RenkerAndreas RolfEfstratios I CharitosMaren WeferlingChristoph LiebetrauEva HerrmannYeong-Hoon ChoiChristian W HammWon Keun KimPublished in: European heart journal. Cardiovascular pharmacotherapy (2022)
The beneficial association between RASI after TAVI and improved survival during follow-up is particularly evident in high-risk patients and may be dose dependent. No superiority was noted in the effectiveness of ACEI or ARB.
Keyphrases
- transcatheter aortic valve implantation
- aortic stenosis
- ejection fraction
- aortic valve
- aortic valve replacement
- end stage renal disease
- newly diagnosed
- randomized controlled trial
- systematic review
- transcatheter aortic valve replacement
- peritoneal dialysis
- prognostic factors
- patient reported outcomes
- atrial fibrillation
- left ventricular